Valuation Gilead Sciences, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 01:30:00 25/07/2026 am IST			5-day change	1st Jan Change
129.31 ^USD	-1.18%		-3.70%	+5.35%

24/07	Gilead Sciences, Inc. Recommends Trodelvy Plus Keytruda In PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer	CI
24/07	Gilead Sciences Says EMA Recommends Trodelvy-Keytruda Combination for Breast Cancer	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	1,07,677	1,00,942	1,15,118	1,52,281	1,60,547	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	5.43%	-	-
Enterprise Value (EV) ¹	1,18,530	1,26,522	1,18,665	1,31,838	1,69,585	1,70,008	1,60,547	1,50,455
Change	-	6.74%	-6.21%	11.1%	28.63%	0.25%	-5.56%	-6.29%
P/E	14.7x	23.6x	18x	243x	18.1x	-46.6x	16.4x	15.1x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	8.16x	6.37x	5.14x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.68x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.28x	4.97x	4.71x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	5.59x	4.97x	4.42x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	30.9x	8.94x	8.37x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	61.5x	10.3x	9x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	211x	12.1x	10.7x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	0.47%	8.24%	9.31%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.296	3.409	3.102
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.55%	2.64%	2.4%
EPS ²	4.93	3.64	4.5	0.38	6.78	-2.776	7.879	8.587
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-119%	43.3%	36.1%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,422	32,283	34,074
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	5,510	17,953	17,972
EBIT ¹	12,548	12,180	10,484	8,520	13,193	2,762	15,576	16,718
Net income ¹	6,225	4,592	5,665	480	8,510	-3,391	9,762	10,457
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	9,460	-	-10,093
Reference price ²	72.61	85.85	81.01	92.37	122.74	129.31	129.31	129.31
Nbr of stocks (in thousands)	12,54,384	12,54,244	12,46,042	12,46,266	12,40,680	12,41,570	-	-
Announcement Date	01/02/22	02/02/23	06/02/24	11/02/25	10/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
GILEAD SCIENCES, INC.	-47.14x	5.65x	31.2x	2.52%	16TCr
ELI LILLY AND COMPANY	35.39x	12.58x	26.43x	0.57%	1,05700Cr
JOHNSON & JOHNSON	27.79x	6.35x	17.58x	2.07%	62TCr
ABBVIE INC.	33.47x	7.59x	15.59x	2.68%	45TCr
ROCHE HOLDING AG	20.98x	4.63x	11.4x	2.86%	34TCr
NOVARTIS AG	21.62x	5.7x	13.97x	2.82%	30TCr
ASTRAZENECA PLC	21.08x	4.45x	12.3x	1.98%	26TCr
NOVO NORDISK A/S	14.13x	5.26x	10.83x	3.54%	22TCr
AMGEN INC.	24.37x	6.41x	11.32x	2.71%	20TCr
PFIZER INC.	12.7x	3.11x	7.85x	6.9%	14TCr
Average	16.44x	6.17x	15.85x	2.87%	37.56TCr
Weighted average by Cap.	24.26x	7.70x	18.12x	2.17%